Gossamer Bio Inc
GOSS2.085USD
+0.085+4.25%
交易中 （美东）报价延迟15分钟
473.76M总市值
亏损市盈率 TTM
关于 Gossamer Bio Inc 公司
Gossamer Bio, Inc. 是一家临床阶段的生物制药公司。该公司专注于开发和商业化用于治疗肺动脉高压 (PAH) 的色拉替尼。其候选产品色拉替尼，也称为 GB002，是一种研究性吸入式小分子血小板衍生生长因子受体 (PDGFR)、集落刺激因子 1 受体 (CSF1R) 和 c-KIT 抑制剂，正在 III 期临床试验中评估其用于治疗 PAH 的效果。与市场上销售的三类 PAH 血管扩张疗法相比，色拉替尼有可能通过解决 PAH 的潜在机制来逆转病理重塑。吸入式色拉替尼旨在作用于 PDGFR、α 和 β 的两种亚型以及 CSF1R 和 c-KIT 通路。除了 PAH 之外，色拉替尼还有望成为治疗与间质性肺病相关的肺动脉高压 (PH-ILD) 的治疗选择。
公司简介
公司代码GOSS
公司名称Gossamer Bio Inc
上市日期Feb 08, 2019
CEOMr. Faheem Hasnain
员工数量144
证券类型Ordinary Share
年结日Feb 08
公司地址3115 Merryfield Row
城市SAN DIEGO
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编92121
电话18586841300
网址https://www.gossamerbio.com/
公司代码GOSS
上市日期Feb 08, 2019
CEOMr. Faheem Hasnain
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Christian Waage
Mr. Christian Waage
Executive Vice President - Technical Operations and Administration
Executive Vice President - Technical Operations and Administration
666.30K
+1.87%
Dr. Richard Aranda, M.D.
Dr. Richard Aranda, M.D.
Chief Medical Officer
Chief Medical Officer
205.95K
+5.92%
Mr. Faheem Hasnain
Mr. Faheem Hasnain
Chairman of the Board, President, Chief Executive Officer, Co-Founder
Chairman of the Board, President, Chief Executive Officer, Co-Founder
120.29K
--
Ms. Caryn Peterson
Ms. Caryn Peterson
Executive Vice President - Regulatory Affairs
Executive Vice President - Regulatory Affairs
49.83K
--
Dr. Thomas O. (Tom) Daniel, M.D.
Dr. Thomas O. (Tom) Daniel, M.D.
Lead Independent Director
Lead Independent Director
38.09K
--
Dr. Sandra Milligan, M.D., J.D.
Dr. Sandra Milligan, M.D., J.D.
Independent Director
Independent Director
32.00K
--
Mr. Russell J. Cox
Mr. Russell J. Cox
Independent Director
Independent Director
7.20K
--
Dr. John D. Quisel, J.D., Ph.D.
Dr. John D. Quisel, J.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Robert (Ob) Smith
Mr. Robert (Ob) Smith
Chief Commercial Officer
Chief Commercial Officer
--
--
Dr. Steven D. Nathan, M.D.
Dr. Steven D. Nathan, M.D.
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Christian Waage
Mr. Christian Waage
Executive Vice President - Technical Operations and Administration
Executive Vice President - Technical Operations and Administration
666.30K
+1.87%
Dr. Richard Aranda, M.D.
Dr. Richard Aranda, M.D.
Chief Medical Officer
Chief Medical Officer
205.95K
+5.92%
Mr. Faheem Hasnain
Mr. Faheem Hasnain
Chairman of the Board, President, Chief Executive Officer, Co-Founder
Chairman of the Board, President, Chief Executive Officer, Co-Founder
120.29K
--
Ms. Caryn Peterson
Ms. Caryn Peterson
Executive Vice President - Regulatory Affairs
Executive Vice President - Regulatory Affairs
49.83K
--
Dr. Thomas O. (Tom) Daniel, M.D.
Dr. Thomas O. (Tom) Daniel, M.D.
Lead Independent Director
Lead Independent Director
38.09K
--
Dr. Sandra Milligan, M.D., J.D.
Dr. Sandra Milligan, M.D., J.D.
Independent Director
Independent Director
32.00K
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 5月17日 周六
更新时间: 5月17日 周六
持股股东
股东类型
持股股东
持股股东
占比
Octagon Capital Advisors LP
8.07%
New Enterprise Associates (NEA)
7.96%
The Vanguard Group, Inc.
5.02%
ARCH Venture Partners
3.54%
Fidelity Management & Research Company LLC
3.34%
Other
72.06%
持股股东
持股股东
占比
Octagon Capital Advisors LP
8.07%
New Enterprise Associates (NEA)
7.96%
The Vanguard Group, Inc.
5.02%
ARCH Venture Partners
3.54%
Fidelity Management & Research Company LLC
3.34%
Other
72.06%
股东类型
持股股东
占比
Hedge Fund
30.00%
Investment Advisor
18.72%
Venture Capital
14.20%
Investment Advisor/Hedge Fund
12.33%
Corporation
2.76%
Research Firm
1.08%
Individual Investor
0.76%
Pension Fund
0.21%
Other
19.95%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
261
181.97M
80.06%
-60.13M
2025Q1
285
180.17M
79.28%
-64.51M
2024Q4
310
181.35M
80.03%
-59.94M
2024Q3
354
184.99M
81.77%
-80.44M
2024Q2
354
192.00M
84.87%
-65.92M
2024Q1
360
205.91M
94.29%
-56.87M
2023Q4
359
215.74M
99.04%
-22.98M
2023Q3
360
211.40M
97.17%
+97.02M
2023Q2
346
75.83M
79.45%
-49.80M
2023Q1
346
90.30M
97.95%
-52.80M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Octagon Capital Advisors LP
18.35M
8.07%
--
--
Mar 31, 2025
New Enterprise Associates (NEA)
18.09M
7.96%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
10.08M
4.44%
+49.73K
+0.50%
Mar 31, 2025
ARCH Venture Partners
8.06M
3.54%
--
--
Mar 31, 2025
Fidelity Management & Research Company LLC
7.59M
3.34%
-340.02K
-4.29%
Mar 31, 2025
Acadian Asset Management LLC
6.36M
2.8%
+1.25M
+24.55%
Mar 31, 2025
SilverArc Capital Management, LLC
6.32M
2.78%
+148.84K
+2.41%
Mar 31, 2025
Palo Alto Investors LP
6.28M
2.76%
-200.00
-0.00%
Mar 31, 2025
Samsara BioCapital, LLC
6.13M
2.7%
--
--
Mar 31, 2025
683 Capital Management LLC
6.10M
2.68%
-875.00K
-12.54%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
ALPS Medical Breakthroughs ETF
0.19%
iShares Micro-Cap ETF
0.05%
Invesco Russell 2000 Dynamic Multifactor ETF
0.02%
iShares Russell 2000 Growth ETF
0.02%
ProShares Hedge Replication ETF
0.01%
Schwab U.S. Small-Cap ETF
0.01%
iShares Russell 2000 ETF
0.01%
Proshares Ultra Russell 2000
0.01%
ProShares UltraPro Russell2000
0.01%
Global X Russell 2000 ETF
0.01%
查看更多
ALPS Medical Breakthroughs ETF
占比0.19%
iShares Micro-Cap ETF
占比0.05%
Invesco Russell 2000 Dynamic Multifactor ETF
占比0.02%
iShares Russell 2000 Growth ETF
占比0.02%
ProShares Hedge Replication ETF
占比0.01%
Schwab U.S. Small-Cap ETF
占比0.01%
iShares Russell 2000 ETF
占比0.01%
Proshares Ultra Russell 2000
占比0.01%
ProShares UltraPro Russell2000
占比0.01%
Global X Russell 2000 ETF
占比0.01%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
